Sugi Predict

Sugi Predict / Compounds / SCHEMBL724089

SCHEMBL724089

SCHEMBL724089

O=C(Cl)c1ccc(Cl)nn1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ JUN P05412 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ NAPRT Q6XQN6 1/20 0.39
▸ LMNA P02545 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ ALDH1A1 P00352 6/20 0.37
▸ MAPT P10636 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ HTT P42858 1/20 0.36
▸ SIRT6 Q8N6T7 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NNMT P40261 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380569 0.81 JUN (0.45) JUNNFKB1NFKB2RELANAPRT
SCHEMBL64708 0.79 NNMT (0.53) JUNNFKB1NFKB2RELALMNA
SCHEMBL1070960 0.79 JUN (0.44) JUNNFKB1NFKB2RELANAPRT
SCHEMBL31753297 0.79 NNMT (0.53) JUNNFKB1NFKB2RELALMNA
SCHEMBL3301092 0.77 JUN (0.42) JUNNFKB1NFKB2RELANAPRT
SCHEMBL28549561 0.76 JUN (0.38) JUNNFKB1NFKB2RELANAPRT
SCHEMBL474101 0.74 MAPK1 (0.47) JUNNFKB1NFKB2RELALMNA
SCHEMBL18339567 0.74 JUN (0.41) JUNNFKB1NFKB2RELALMNA
SCHEMBL31306809 0.74 P2RX7 (0.52) JUNNFKB1NFKB2RELALMNA
SCHEMBL8600253 0.74 P2RX7 (0.52) JUNNFKB1NFKB2RELALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658644-A1 2-(PYRIDAZIN-3-YL)-5-(TRIFLUOROMETHYL)PHENOLS AS NLRP3 INHIBITORS Janssen Pharmaceutica NV (BE) 2025-12-10 — — EP disclosed
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 — — US disclosed
WO-2025036269-A1 COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF 青岛普泰科生物医药科技有限公司 2025-02-20 — — WO disclosed
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 — — EP disclosed
WO-2024160690-A1 2-(PYRIDAZIN-3-YL)-5-(TRIFLUOROMETHYL)PHENOLS AS NLRP3 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-08-08 — — WO disclosed
US-12012390-B2 Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2024-06-18 — — US disclosed
CN-112601743-B Flavone compounds for the treatment and prevention of hepatitis b virus diseases 豪夫迈·罗氏有限公司 2023-12-19 — — CN disclosed
EP-3849966-B1 FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
EP-3849966-B1 FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
WO-2023180388-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-09-28 — — WO disclosed
US-20040242581-A1 Substituted heterocyclic carboxamides with antithrombotic activity ELI LILLY AND COMPANY 2004-12-02 — — US disclosed
EP-1456175-A1 SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY ELI LILLY AND COMPANY (US) 2004-09-15 — — EP disclosed
US-20040097491-A1 Substituted heterocyclic amides HERRON DAVID KENT (US) 2004-05-20 — — US disclosed
WO-2003050088-A1 SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY ELI LILLY AND COMPANY (US) 2003-06-19 — — WO disclosed
CN-1110495-C Arylalkyl diazinones MERCK PATENT GMBH (DE) 2003-06-04 — — CN disclosed
EP-1307444-A2 SUBSTITUTED HETEROCYCLIC AMIDES ELI LILLY AND COMPANY (US) 2003-05-07 — — EP disclosed
WO-2002010154-A2 SUBSTITUTED HETEROCYCLIC AMIDES ELI LILLY AND COMPANY (US) 2002-02-07 — — WO disclosed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 — — WO disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 — — US disclosed
CN-1157287-A Arylalkyl diazinones MERCK PATENT GMBH (DE) 1997-08-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012390-B2 Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease PCNA, DNMT1, DNMT3B JUN 400/4885NFKB1 591/4885NFKB2 631/4885
US-20040242581-A1 Substituted heterocyclic carboxamides with antithrombotic activity F11, SERPINC1, TFPI JUN 2024/4885NFKB1 1491/4885NFKB2 3046/4885
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR JUN 1813/4885NFKB1 1612/4885NFKB2 1447/4885
US-20040097491-A1 Substituted heterocyclic amides F12, F11, F8 JUN 1062/4885NFKB1 1358/4885NFKB2 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.